FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to recombinant systems for expression of immunogenic proteins, and can be used in medicine to stimulate immune response. Vector for expression in a mammalian cell comprising a first nucleotide sequence which codes a secreted fused gp96-Ig fusion protein, and a second nucleotide sequence which is co-expressed with said first nucleotide sequence and which codes a fusion protein of costimulatory T-cells. T-cell fusion protein is selected from OX40L-Ig or a portion of said protein which binds to OX40, ICOSL-Ig or a portion of said protein which binds to ICOS, 4-lBBL-Ig or a portion of said protein which binds to 4-1BBR, TL1A-Ig or a portion of said protein which binds to TNFRSF25, GITRL-Ig or a portion of said protein which binds to GITR, CD40L-Ig or a portion of said protein which binds to CD40, and CD70-Ig or a portion of said protein that binds with CD27.
EFFECT: invention provides enhanced activation of antigen-specific T-cells during co-expression of fused protein, which is costimulating T-cells, with secreted fused gp96-Ig protein in a subject.
41 cl, 18 dwg, 3 ex
| Title |
Year |
Author |
Number |
| MONOSPECIFIC AND BISPECIFIC PROTEINS WITH IMMUNE CHECKPOINT REGULATION FOR CANCER TREATMENT |
2018 |
- Yu, Zhun-Zhe
- Khsu, Ching-Khsuan
- Khuan, Po-Lin
- Kan, Khung-Tsaj
- Chan, Tin-I
- Khsiekh, Khsin-Ta
- Kher, Dzheng-Khorng
|
RU2793167C2 |
| IMMUNOACTIVATING ANTIGEN-BINDING MOLECULE |
2015 |
- Igava Tomoyuki
- Miyazaki Taro
- Taniguchi Kendzi
- Khironiva Naoka
|
RU2722788C2 |
| COMPOSITIONS AND METHODS FOR CONNECTING EXTRACELLULAR DOMAINS OF TYPE I AND TYPE II AS HETEROLOGOUS CHIMERIC PROTEINS |
2016 |
- Schreiber Taylor
- Fromm George
- De Silva Suresh
- Schilling Neal
|
RU2766200C1 |
| FUSED MOLECULES DERIVED FROM CHOLIX-TOXIN FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE LOADS |
2015 |
- Mrsny Randall J.
- Mahmood Tahir
|
RU2723178C2 |
| TGFβR2 MOLECULE WITH TRUNCATED EXTRACELLULAR DOMAIN, FUSION PROTEIN OF TGFβR2 MOLECULE WITH TRUNCATED EXTRACELLULAR DOMAIN, AND ANTI-EGFR ANTIBODIES, AND ANTI-TUMOUR USE OF FUSED PROTEIN |
2021 |
- Shie Lianzy
- San Chanjen
- Guo Erong
|
RU2824199C1 |
| LIGAND-BINDING MOLECULE WITH REGULATED LIGAND-BINDING ACTIVITY |
2017 |
- Igawa Tomoyuki
- Ishikawa Hiroyuki
|
RU2803067C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES AND METHODS OF THEIR USE |
2019 |
- Ellerman, Diego
- Dzhunttila, Timu, T.
- Lombana, Tvila, Noell
- Slaga, Dionisos
- Spiss, Kristof
|
RU2800779C2 |
| LIBRARY OF CONCENTRATION-DEPENDENT BINDING MOLECULES |
2012 |
- Igava Tomoyuki
- Isii Sinya
- Funaki Mikho
- Khironiva Naoka
- Simidzu Syun
|
RU2732151C2 |
| MODIFIED NON-NATURAL NKG2D LIGANDS WHICH SELECTIVELY DELIVER ATTACHED HETEROLOGOUS MOLECULES TO NON-NATURAL NKG2D RECEPTORS ON CAR CELLS |
2020 |
- Kim, Kaman
- Kileen, Nigel
- Herzig, Eytan
- Greene, Warner
|
RU2823728C2 |
| ANTIGEN-BINDING MOLECULE CAPABLE OF MULTIPLE BINDING TO A VARIETY OF ANTIGEN MOLECULES |
2018 |
- Igava Tomoyuki
- Isii Sinya
- Funaki Mikho
- Khironiva Naoka
- Maeda Atsukhiko
- Nedzu Dzyuniti
- Rujke Esinao
- Baba Takesi
- Simidzu Syun
|
RU2757786C2 |
